Moclobemide

Moclobemide
Molecular structure of moclobemide
3D representation of a moclobemide molecule
Clinical data
Trade namesAmira, Aurorix, Clobemix, Depnil, Manerix, others
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: B3
Routes of
administration
Oral
Drug classReversible inhibitor of monoamine oxidase A, antidepressant
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class C1 (Other controlled substances)
  • CA: ℞-only
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability55–95% (increases with repeat administration)
Protein binding50%
MetabolismLiver
Elimination half-life1–2 hours, 4 hours (elderly)
ExcretionKidney, Faecal (<5%)
Identifiers
  • 4-chloro-N-(2-morpholin-4-ylethyl)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.163.935
Chemical and physical data
FormulaC13H17ClN2O2
Molar mass268.74 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)C(=O)NCCN2CCOCC2
  • InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17) checkY
  • Key:YHXISWVBGDMDLQ-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the United Kingdom and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.

Moclobemide differs from the classic monoamine oxidase inhibitors (MAOIs) in that it selectively and reversibly inhibits monoamine oxidase A. Its interaction with dietary tyramine is consequently weaker and shorter-lived; special dietary restrictions are generally not required at standard therapeutic doses, although prescribing information advises avoiding large amounts of tyramine-rich foods. With classic MAOIs, a tyramine-restricted diet remains recommended because excessive tyramine can provoke a hypertensive reaction; however, modern food-production standards have reduced tyramine levels in most foods, and contemporary guidance focuses on a relatively small number of higher-risk foods. Moclobemide nevertheless has clinically important interactions with some serotonergic and sympathomimetic drugs.

Moclobemide was first introduced for medical use in 1989.